Yukon Biosciences

Yukon Biosciences is a clinical-stage Swiss biotechnology company focused on developing innovative targeted radionuclide therapies (TRTs) and theranostic regimens to treat difficult-to-cure cancers. Spun off in 2024 from the Paul Scherrer Institute (PSI) and University Hospital Basel, the company leverages a theranostic approach that combines therapeutic radiopharmaceuticals with PET imaging to monitor treatment success. Its lead asset, Lu-177 PP-F11N (also known as [177Lu]Lu-PP-F11N), is a radiolabeled minigastrin analog targeting the cholecystokinin-2 receptor (CCK2R), which is highly expressed in medullary thyroid carcinoma (MTC) and other cancers. Yukon Biosciences is advancing a pipeline of five assets centered around the PP-F11N peptide, aiming to improve patient survival and quality of life through optimized tumor uptake and nephroprotective regimens.